Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Nelarabine (506U78) is a soluble pro-drug of 9-β-D- arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95% CI, 11, 56), and the median overall survival was 20 weeks (95% CI, 13, 36). The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.

Original languageEnglish (US)
Pages (from-to)5136-5142
Number of pages7
JournalBlood
Volume109
Issue number12
DOIs
StatePublished - Jun 15 2007

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-cells
Refractory materials
Confidence Intervals
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
T-Cell Lymphoma
Neoplasms
Consciousness Disorders
Deoxyguanosine
Survival
Prodrugs
Neurology
Neutropenia
Nervous System
Disease-Free Survival
Toxicity
Appointments and Schedules
nelarabine
Derivatives

ASJC Scopus subject areas

  • Hematology

Cite this

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma : Cancer and Leukemia Group B study 19801. / DeAngelo, Daniel J.; Yu, Daohai; Johnson, Jeffrey L.; Coutre, Steven E.; Stone, Richard M.; Stopeck, Alison T; Gockerman, Jon P.; Mitchell, Beverly S.; Appelbaum, Frederick R.; Larson, Richard A.

In: Blood, Vol. 109, No. 12, 15.06.2007, p. 5136-5142.

Research output: Contribution to journalArticle

DeAngelo, Daniel J. ; Yu, Daohai ; Johnson, Jeffrey L. ; Coutre, Steven E. ; Stone, Richard M. ; Stopeck, Alison T ; Gockerman, Jon P. ; Mitchell, Beverly S. ; Appelbaum, Frederick R. ; Larson, Richard A. / Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma : Cancer and Leukemia Group B study 19801. In: Blood. 2007 ; Vol. 109, No. 12. pp. 5136-5142.
@article{b5a0deea1ab646febf9f00806722d60e,
title = "Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801",
abstract = "Nelarabine (506U78) is a soluble pro-drug of 9-β-D- arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82{\%}) patients were male. The rate of complete remission was 31{\%} (95{\%} confidence interval [CI], 17{\%}, 48{\%}) and the overall response rate was 41{\%} (95{\%} CI, 26{\%}, 58{\%}). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37{\%} and 26{\%} of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95{\%} CI, 11, 56), and the median overall survival was 20 weeks (95{\%} CI, 13, 36). The 1-year overall survival was 28{\%} (95{\%} CI, 15{\%}, 43{\%}). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.",
author = "DeAngelo, {Daniel J.} and Daohai Yu and Johnson, {Jeffrey L.} and Coutre, {Steven E.} and Stone, {Richard M.} and Stopeck, {Alison T} and Gockerman, {Jon P.} and Mitchell, {Beverly S.} and Appelbaum, {Frederick R.} and Larson, {Richard A.}",
year = "2007",
month = "6",
day = "15",
doi = "10.1182/blood-2006-11-056754",
language = "English (US)",
volume = "109",
pages = "5136--5142",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma

T2 - Cancer and Leukemia Group B study 19801

AU - DeAngelo, Daniel J.

AU - Yu, Daohai

AU - Johnson, Jeffrey L.

AU - Coutre, Steven E.

AU - Stone, Richard M.

AU - Stopeck, Alison T

AU - Gockerman, Jon P.

AU - Mitchell, Beverly S.

AU - Appelbaum, Frederick R.

AU - Larson, Richard A.

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Nelarabine (506U78) is a soluble pro-drug of 9-β-D- arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95% CI, 11, 56), and the median overall survival was 20 weeks (95% CI, 13, 36). The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.

AB - Nelarabine (506U78) is a soluble pro-drug of 9-β-D- arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95% CI, 11, 56), and the median overall survival was 20 weeks (95% CI, 13, 36). The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.

UR - http://www.scopus.com/inward/record.url?scp=34250003760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250003760&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-11-056754

DO - 10.1182/blood-2006-11-056754

M3 - Article

C2 - 17344466

AN - SCOPUS:34250003760

VL - 109

SP - 5136

EP - 5142

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -